Ordering
Available Variants10 mg
CHA.65153-10mg
Price
€157.60
Available – Dispatch in 14 days
50 mg
CHA.65153-50mg
Price
€503.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.65153-10mg | €157.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.65153-50mg | €503.20 |
≥98% (HPLC), histamine H1 receptor antagonist, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C19H19ClN2 |
|---|---|
| CAS Number | 100643-71-8 |
| Molecular Weight | 310.82 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329798668 |
| NACRES | NA.32 |
| MDL number | MFCD00871949 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 1 |
| flash_point_f | 390.2 °F - Pensky-Martens closed cup |
| flash_point_c | 199 °C - Pensky-Martens closed cup |
Technical Overview & Applications Use-case context
Desloratadine, with a chemical formula of C19H19ClN2, is a non-sedating, long-acting histamine antagonist. It is a major active metabolite of loratadine and is primarily used to treat allergic rhinitis and chronic idiopathic urticaria. Desloratadine functions by selectively blocking peripheral histamine H1-receptors, thereby reducing the allergic response. Its pharmacokinetic profile is characterized by rapid absorption, high bioavailability, and a terminal half-life of approximately 27 hours, allowing for once-daily dosing. Desloratadine has been shown to be effective in alleviating symptoms of allergic rhinitis, including nasal congestion, rhinorrhea, and pruritus, as well as reducing the severity of urticarial lesions and pruritus in patients with chronic idiopathic urticaria, with a favorable safety and tolerability profile. Its efficacy and safety have been established in numerous clinical trials, supporting its use as a treatment option for these conditions.
